Coronary Artery DiseaseDACAB-FE-10YNCT07480629
The 10-Year Extended Follow-up of the DACAB Trial
An observational study of Coronary Artery Disease and CABG, run by Ruijin Hospital at 1 site in China.
Trial summary
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- 15 Mar 2026to 30 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All 500 patients who were enrolled and randomized in the DACAB trial (NCT02201771) between July 2014 and November 2015. These patients underwent elective isolated coronary artery bypass grafting (CABG) with saphenous vein grafting at six tertiary hospitals in China. For this 10-year extended follow-up study, all original DACAB participants are eligible, regardless of their vital status or medication use during the follow-up period. Information on deceased participants will be collected from medical records, family members, or the national China Centre for Disease Control database to minimize loss to follow-up bias.
Who may be able to join
- Original enrollment and randomization in the DACAB trial
Who cannot join
- Who explicitly refuse to provide informed consent for the 10-year follow-up
Trial locations and contacts
1 site in 1 country.
China1 site
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai
About this study
Official title: The 10-Year Extended Follow-up of the Different Antiplatelet Strategies After Coronary Artery Bypass Grafting Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are:
Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone?
Read more
What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies?
Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade.
Participants will:
Be contacted by telephone by the central study team for a one-time follow-up interview.
Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up.
Report their current use of medications, including antiplatelet and other cardiovascular drugs.
Allow researchers to request relevant medical records to verify any reported clinical events.
- Keywords
- Coronary Artery Bypass Grafting (CABG), Antiplatelet Therapy, Ticagrelor, Aspirin, Dual Antiplatelet Therapy (DAPT), Major Adverse Cardiovascular Events (MACE), Long-Term Follow-Up, DACAB, DACAB-FE
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ticagrelor Plus Aspirin Group | Patients originally randomized to receive ticagrelor 90 mg twice daily plus aspirin 100 mg once daily for one year after CABG in the DACAB trial | |
| Ticagrelor Monotherapy Group | Patients originally randomized to receive ticagrelor 90 mg twice daily for one year after CABG in the DACAB trial. | |
| Aspirin Monotherapy Group | Patients originally randomized to receive aspirin 100 mg once daily for one year after CABG in the DACAB trial. |
What is being measured
The primary outcome is the main question the study is designed to answer.
4-Point Major Adverse Cardiovascular Events (4P-MACE)
Time from randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, or coronary revascularization.
Measured: From randomization to completion of 10-year follow-up
Secondary outcomes (8)
5P-MACE
Time from original randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, coronary repeat revascularization, or other cardiovascular-related rehospitalization.
Measured: From randomization to completion of 10-year follow-up
3P-MACE
Time from randomization to the first occurrence of a composite of cardiovascular death, myocardial infarction, or stroke.
Measured: From randomization to 10-year follow-up
All-Cause Death
Time from original randomization to death from any cause.
Measured: From randomization to 10-year follow-up
Cardiovascular Death
Time from original randomization to death from cardiovascular causes, including death of unknown cause.
Measured: From randomization to 10-year follow-up
Myocardial Infarction
Time from original randomization to the first occurrence of myocardial infarction.
Measured: From randomization to 10-year follow-up
Stroke
Time from original randomization to the first occurrence of stroke (including ischemic and hemorrhagic stroke).
Measured: From randomization to 10-year follow-up
Coronary Repeat Revascularization
Time from original randomization to the first occurrence of any post-procedural PCI or repeat CABG
Measured: From randomization to 10-year follow-up
Other Cardiovascular-Related Rehospitalization
Time from original randomization to the first occurrence of hospitalization due to other cardiovascular causes besides those included in 4P-MACE, such as unstable angina, heart failure, arrhythmia, aortic syndrome, or peripheral vascular disease.
Measured: From randomization to 10-year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2026
- Study start15 Mar 2026
- Primary completion20 Jul 2026
- Study completion30 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Ruijin HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ruijin Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhu yunpeng, Ruijin Hospital
- Investigators
- Qiang Z Zhao, MD, Principal investigator, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaYunpeng Zhu, MD, Study director, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07480629
- Sponsor's protocol ID
- KY-2026-104
- Acronym
- DACAB-FE-10Y
- Status last verified
- Aug 2026
- First submitted
- 13 Mar 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Zhu Y, Zhang W, Dimagli A, Han L, Cheng Z, Mei J, Chen X, Wang X, Zhou Y, Xue Q, Hu J, Tang M, Wang R, Song Y, Kang L, Redfors B, Gaudino M, Zhao Q. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024 Jun 11;385:e075707. doi: 10.1136/bmj-2023-075707.
PubMed 38862179Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, Wang X. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA. 2018 Apr 24;319(16):1677-1686. doi: 10.1001/jama.2018.3197.
PubMed 29710164
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The 10-Year Extended Follow-up of the Different Antiplatelet Strategies After Coronary Artery Bypass Grafting Trial
- ClinicalTrials.gov ID
- NCT07480629
- Acronym / sponsor ID
- DACAB-FE-10Y / KY-2026-104
- Keywords
- Coronary Artery Bypass Grafting (CABG), Antiplatelet Therapy, Ticagrelor, Aspirin, Dual Antiplatelet Therapy (DAPT), Major Adverse Cardiovascular Events (MACE), Long-Term Follow-Up, DACAB
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 500 participants (actual)
- Lead sponsor
- Ruijin HospitalUniversity, hospital or other
- Study start
- 15 Mar 2026 (actual)
- Primary completion
- 20 Jul 2026 (actual)
- Study completion
- 30 Jul 2026 (actual)
- First posted
- 18 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are:
Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone?
What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies?
Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade.
Participants will:
Be contacted by telephone by the central study team for a one-time follow-up interview.
Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up.
Report their current use of medications, including antiplatelet and other cardiovascular drugs.
Allow researchers to request relevant medical records to verify any reported clinical events.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Ticagrelor Plus Aspirin Group | – | –Patients originally randomized to receive ticagrelor 90 mg twice daily plus aspirin 100 mg once daily for one year after CABG in the DACAB trial |
| Ticagrelor Monotherapy Group | – | –Patients originally randomized to receive ticagrelor 90 mg twice daily for one year after CABG in the DACAB trial. |
| Aspirin Monotherapy Group | – | –Patients originally randomized to receive aspirin 100 mg once daily for one year after CABG in the DACAB trial. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All 500 patients who were enrolled and randomized in the DACAB trial (NCT02201771) between July 2014 and November 2015. These patients underwent elective isolated coronary artery bypass grafting (CABG) with saphenous vein grafting at six tertiary hospitals in China. For this 10-year extended follow-up study, all original DACAB participants are eligible, regardless of their vital status or medication use during the follow-up period. Information on deceased participants will be collected from medical records, family members, or the national China Centre for Disease Control database to minimize loss to follow-up bias.
Key inclusion criteria (1 listed)
- Original enrollment and randomization in the DACAB trial
Key exclusion criteria (1 listed)
- Who explicitly refuse to provide informed consent for the 10-year follow-up
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
4-Point Major Adverse Cardiovascular Events (4P-MACE)
Time frame: From randomization to completion of 10-year follow-up
Time from randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, or coronary revascularization.
8 secondary outcomes
5P-MACE
Time frame: From randomization to completion of 10-year follow-up
3P-MACE
Time frame: From randomization to 10-year follow-up
All-Cause Death
Time frame: From randomization to 10-year follow-up
Cardiovascular Death
Time frame: From randomization to 10-year follow-up
Myocardial Infarction
Time frame: From randomization to 10-year follow-up
Stroke
Time frame: From randomization to 10-year follow-up
Coronary Repeat Revascularization
Time frame: From randomization to 10-year follow-up
Other Cardiovascular-Related Rehospitalization
Time frame: From randomization to 10-year follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Background: PubMed 38862179Zhu Y, Zhang W, Dimagli A, Han L, Cheng Z, Mei J, Chen X, Wang X, Zhou Y, Xue Q, Hu J, Tang M, Wang R, Song Y, Kang L, Redfors B, Gaudino M, Zhao Q. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024 Jun 11;385:e075707. doi: 10.1136/bmj-2023-075707.
- Background: PubMed 29710164Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, Wang X. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA. 2018 Apr 24;319(16):1677-1686. doi: 10.1001/jama.2018.3197.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Qiang Z Zhao, MD principal investigator
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yunpeng Zhu, MD study director
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and CABG, run by Ruijin Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
4-Point Major Adverse Cardiovascular Events (4P-MACE) (time frame: From randomization to completion of 10-year follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07480629, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.